[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622487":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":64,"collaborators":68,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":23,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":94,"whyStopped":23,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Universiti Sains Malaysia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Daily 6-drops of non-GMO corn starch in medium-chain triglyceride oil",[13],"Other: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Probiotic","EXPERIMENTAL","Daily 6-drops of Bifidobacterium animalis subsp. lactis B94, Lacticaseibacillus helveticus R0052 in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1.5 × 109 CFU\u002Fday)",[19],"Other: Probiotic",[21,24],{"type":6,"name":9,"description":11,"armGroupLabels":22,"otherNames":23},[9],null,{"type":6,"name":15,"description":17,"armGroupLabels":25,"otherNames":23},[15],[27],{"name":28,"affiliation":29,"role":30},"Ai Zhou, Ph.D.","Tsinghua University Science and Technology","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":23,"email":36},"Yuan Jie, M.Sc.","CONTACT","822137027899","peanut.yuan@diprobio.com",{"name":38,"role":34,"phone":39,"phoneExt":23,"email":40},"Min Tze Liong, Ph.D.","6046532114","mintze.liong@usm.my",[42,56],{"facility":29,"status":23,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Haidian","Beijing Municipality","100080","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.28868,39.99064,{"lat":52,"lon":51},[55],{"name":33,"role":34,"phone":35,"phoneExt":23,"email":36},{"facility":5,"status":23,"city":57,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":23,"geoPoint":23,"contacts":61},"Pulau Pinang","11800","Malaysia","MY",[62],{"name":63,"role":34,"phone":39,"phoneExt":23,"email":40},"Min Tze Liong, Ph.D",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Min-Tze LIONG","Prof.",[69],{"name":70,"class":6},"Tsinghua University","100622487","phase-2-the-effect-of-probiotics-on-gut-microbiota-changes-in-healthy-chinese-adults-during-short-term-european-travel-a-randomised-double-blind-placebo-controlled-clinical-trial-100622487",false,"NCT07384260","The Effect of Probiotics on Gut Microbiota Changes in Healthy Chinese Adults During Short-Term European Travel: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial","The Effect of","Inclusion criteria:\n\n1. Aged 18-65 years, regardless of gender;\n2. Planning to undertake a short-term round-trip journey to Europe (within 7 days);\n3. Able to understand and willing to comply with the study protocol, and to cooperate with study procedures;\n4. Voluntarily sign the informed consent form before any study-related procedures are initiated.\n\nExclusion criteria:\n\n1. Diseases that may affect the evaluation of trial results, such as immune dysfunction, severe renal\u002Fhepatic dysfunction, severe cardiovascular disease, malignant tumors, acute or chronic infections, etc.;\n2. Use of probiotic preparations, antibiotics, hormones, immunosuppressants, biological agents, or JAK inhibitors within 4 weeks;\n3. Subjects with diagnosed or uncontrolled parasitic infections;\n4. Patients receiving long-term medication for chronic diseases;\n5. Patients with severe organic lesions in the thyroid, heart, brain, lungs, kidneys, or musculoskeletal system;\n6. Patients with a history of or currently diagnosed mental illness;\n7. Patients on long-term corticosteroid therapy;\n8. Use of growth hormone, γ-aminobutyric acid (GABA), lysine, inositol, or vitamin B12;\n9. Presence of uncontrolled, clinically significant laboratory abnormalities that may affect data interpretation or subject participation;\n10. Participation in other clinical intervention studies involving drugs, dietary supplements, probiotics, or prebiotics within the past 4 weeks;\n11. Presence of severe infections or major trauma deemed by the investigator to potentially affect outcomes, or having undergone moderate to major surgery within the past month;\n12. Known allergy to any component of the probiotic product;\n13. Subjects deemed unsuitable for participation by the investigator for any other reason.",true,"ALL","18 Years","65 Years",{"count":83,"type":84},40,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","This study aims to evaluate the efficacy of a probiotic complex (containing Bifidobacterium animalis subsp. lactis B94 and Lacticaseibacillus helveticus R0052) in maintaining gut microbiota homeostasis and supporting physiological and psychological stability among healthy Chinese adults during short-term travel to Europe.",[90],"Healthy Adult",[92,93],"probiotic","international travel","NOT_YET_RECRUITING","2026-01-28",{"date":97,"type":98},"2026-02-03","ACTUAL",{"date":100,"type":84},"2026-02-01",{"date":102,"type":84},"2027-01-31",{"name":66,"class":6},2]